What Was Offered in These Contracts?
TL/DR –
Senator Elizabeth Warren has questioned Chris Klomp, President Trump’s nominee to be Deputy Secretary of the Department of Health and Human Services (HHS), regarding secret deals with drug companies that were allegedly made by the Trump administration. These Most Favored Nation agreements are claimed by Trump to have cut prescription drug prices by as much as 600%, though the specifics of these deals, promised to be disclosed by HHS Secretary Robert F. Kennedy Jr., have not been made public. Senator Warren has challenged these claims and demanded transparency, suggesting that the drug companies may have received beneficial terms such as tariff relief or fast-track FDA approval in these hidden deals.
“`html
Senator Elizabeth Warren Questions Trump’s Nominee on Secret Drug Deals
In a recent Senate Finance Committee hearing, U.S. Senator Elizabeth Warren (D-Mass.) interrogated Chris Klomp, who has been nominated by President Trump as Deputy Secretary of the Department of Health and Human Services (HHS). The focus of her questioning revolved around the secret deals that President Trump has made with pharmaceutical companies.
President Trump has previously boasted about the administration’s Most Favored Nation (MFN) agreements with pharmaceutical companies. He claims these agreements have led to a reduction in prescription drug prices by up to 600%. Senator Warren noted that if this were true, “companies should be paying you to take their drugs.” However, the specifics of these deals have not been made publicly available by either President Trump or the pharmaceutical companies involved.
Previously, in April 2026, Senator Warren asked HHS Secretary Robert F. Kennedy Jr. about these deals during another Senate Finance Committee hearing. Secretary Kennedy, with Mr. Klomp in attendance, confirmed he would disclose the deals to the public. Despite this promise, Secretary Kennedy has not followed through.
“Mr. Klomp, was Secretary Kennedy lying when he said he would make those deals available to us?” inquired Senator Warren. When Mr. Klomp was asked to explain why these deals had not been made public, he failed to provide an explanation.
“Show me the receipts,” Senator Warren insisted.“Five months ago, the Secretary promised that he would deliver those contracts. It’s been five months, and we don’t have them.”
The senator also highlighted the issue of pharmaceutical companies presenting these agreements in such a way that they don’t seem likely to affect their financial outlook. For instance, Insight Corporation, a biotech company, stated earlier this month that it does not anticipate its deal with the Trump administration to significantly impact its future financial outlook. Pfizer’s deal has been described as “immaterial,” and both Novartis and Roche have made similar statements about their respective deals.
Further, Senator Warren questioned whether the pharmaceutical companies may have received any incentives to engage in these secret deals with the Trump administration. “I want to know what was given away in these contracts,” Senator Warren stated, querying whether these companies received tariff relief, exemptions from drug pricing demonstrations in Medicare, fast-track FDA approval, or higher prices abroad instead of lower prices in the U.S.
“I want to see what the deal is, and until then, you can stop telling us it was all great for the American people, but you just refused to show us the receipts. That’s not how oversight works,” Senator Warren asserted.
Senator Warren’s efforts to challenge Big Pharma and lower drug prices through all available government resources have been ongoing. These initiatives include holding the Trump administration accountable for secret pricing deals with drug companies, prohibiting joint ownership of pharmacy benefit managers and pharmacies, and demanding transparency in deals made with various pharmaceutical companies.
A video recording of the exchange is available on YouTube.
“`
—
Read More US Economic News